| Members |
targetComponentId |
| Tocilizumab 20mg/mL conventional release solution for injection (product) |
Tocilizumab only product in parenteral dose form |
| Tocilizumab 20mg/mL solution for intravenous infusion (product) |
Tocilizumab only product in parenteral dose form |
| Tocopherol |
vitamine E et/ou dérivés (substance) |
| Toe flap |
Flap (substance) |
| Tolnaftate+chlorhexidine hydrochloride (product) |
Product containing chlorhexidine and tolnaftate (medicinal product) |
| Tolterodine 4mg m/r capsule (product) |
Product containing only tolterodine in oral dose form (medicinal product form) |
| Tolterodine L-tartrate 4mg m/r capsule (product) |
Product containing only tolterodine in oral dose form (medicinal product form) |
| Tolterodine L-tartrate 4mg m/r capsule (product) |
Product containing only tolterodine in oral dose form (medicinal product form) |
| Tolterodine L-tartrate 4mg prolonged-release oral capsule (product) |
Product containing only tolterodine in oral dose form (medicinal product form) |
| Tolterodine tartrate 2mg m/r capsule (product) |
Product containing only tolterodine in oral dose form (medicinal product form) |
| Tolterodine tartrate 2mg prolonged-release oral capsule (product) |
Product containing only tolterodine in oral dose form (medicinal product form) |
| Tolterodine tartrate 4mg m/r capsule (product) |
Product containing only tolterodine in oral dose form (medicinal product form) |
| Toluene diisocyanate specific extract (product) |
Toluene-2-4-diisocyanate |
| Tomato - dietary |
Tomato (substance) |
| Tomilol |
Timolol (substance) |
| Tongue flap |
Flap (substance) |
| Tonsil (& peritonsillar region) (& peritonsillar region) (body structure) |
structure de la tonsille palatine (structure corporelle) |
| Tooth attrition (disorder) |
Excessive attrition of teeth (disorder) |
| Tooth decalcification (finding) |
Incipient enamel caries |
| Topical compound dexamethasone preparation allergy |
Allergy to dexamethasone |
| Topical compound hydrocortisone preparation allergy |
Allergy to hydrocortisone (finding) |
| Topical corticosteroid, group I (substance) |
Glucocorticoid (substance) |
| Topical corticosteroid, group II (substance) |
Glucocorticoid (substance) |
| Topical corticosteroid, group III (substance) |
Glucocorticoid (substance) |
| Topical corticosteroid, group IV (substance) |
Glucocorticoid (substance) |
| Topical corticosteroid, group V (substance) |
Glucocorticoid (substance) |
| Topical corticosteroid, group VI (substance) |
Glucocorticoid (substance) |
| Topical dexamethasone allergy |
Allergy to dexamethasone |
| Topical estradiol allergy |
Allergy to estradiol (finding) |
| Topical hydrocortisone allergy |
Allergy to hydrocortisone (finding) |
| Topical prednisolone allergy |
Allergy to prednisolone |
| Topical salicylic acid allergy |
Allergy to salicylic acid (finding) |
| Topical selenium (substance) |
sélénium |
| Topical sulfur (substance) |
soufre (substance) |
| Topotecan 1mg powder for infusion solution vial (product) |
Topotecan (as topotecan hydrochloride) 1 mg powder for solution for injection vial |
| Torday's elephant shrew |
Family Macroscelididae |
| Torek operation for orchiopexy |
Orchidopexy |
| Torsemide 10mg/mL injection solution ampule (product) |
Product containing only torasemide in parenteral dose form (medicinal product form) |
| Torulopsis |
Genus Candida (organism) |
| Torulopsis candida |
Candida saitoana |
| Torulopsis glabrata |
Candida glabrata (organism) |
| Torulopsis pintolopesii |
Candida pintolopesii |
| Total biopterins |
Substance with biopterin structure (substance) |
| Total estimated daily energy intake |
Estimated quantity of intake of energy in 24 hours (observable entity) |
| Tourette's disorder (disorder) |
syndrome de Gilles de la Tourette |
| toxémie gravidique |
prééclampsie |
| Toxic effect |
Poisoning |
| Toxic effect from eating shellfish (disorder) |
Toxic effect from eating shellfish (disorder) |
| Toxic effect from noxious substance eaten as food, NEC (disorder) |
Toxic effect of noxious substance eaten as food |
| Toxic effect of chiefly nonmedicinal substance, NEC (disorder) |
effet toxique d'une substance essentiellement non médicinale |
| Toxic effect of hydrocarbon gas, NEC |
Toxic effect of hydrocarbon gas |
| Toxic effect of nitroderivatives and aminoderivatives of benzene and its homologues |
Poisoning caused by substance with benzene structure (disorder) |
| Toxic effect of non-petroleum-based solvent (disorder) |
Toxic effect of nonpetroleum-based solvent |
| Toxic effect of other alcohol, NEC |
Toxic effect of alcohol |
| Toxic effect of other nonpetroleum-based solvent, NEC |
Toxic effect of nonpetroleum-based solvent |
| Toxic encephalopathy (disorder) |
Toxic encephalopathy |
| Toxic porphyria, NEC |
Porphyria due to toxic effect of substance |
| Toxoplasma hepatitis (disorder) |
Hepatitis caused by Toxoplasma gondii |
| Toy in nose causing respiratory obstruction (event) |
Obstruction of respiratory tract caused by toy in nose (disorder) |
| jouet ou gadget |
jouet (objet physique) |
| Toy or novelty causing toxic effect |
Toy causing toxic effect |
| Tracheal endoscopy: [diagnostic rigid NOS] or [NEC] |
Endoscopy of trachea using rigid bronchoscope (procedure) |
| Tracheostomy site (morphologic abnormality) |
Tracheostomy stoma (morphologic abnormality) |
| Tracheostomy, emergency procedure by cricothyroid membrane approach |
Emergency cricothyroidotomy |
| Tramadol hydrochloride 300mg m/r capsule (product) |
Product containing only tramadol in oral dose form (medicinal product form) |
| Tramadol hydrochloride 300mg prolonged-release oral capsule (product) |
Product containing only tramadol in oral dose form (medicinal product form) |
| Tramadol hydrochloride 50mg soluble tablet (product) |
Product containing precisely tramadol hydrochloride 1 milligram/1 milliliter conventional release oral solution (clinical drug) |
| Tramazoline hydrochloride+dexamethasone isonicotinate (product) |
Product containing dexamethasone and tramazoline (medicinal product) |
| Trandolapril allergy |
Non-allergic hypersensitivity to trandolapril (finding) |
| Trandolapril+verapamil hydrochloride (product) |
Product containing trandolapril and verapamil (medicinal product) |
| Trandolapril+verapamil hydrochloride 1mg/240mg m/r tablet (product) |
Product containing only trandolapril and verapamil in oral dose form (medicinal product form) |
| Trandolapril+verapamil hydrochloride 1mg/240mg prolonged-release oral tablet (product) |
Product containing only trandolapril and verapamil in oral dose form (medicinal product form) |
| Trandolapril+verapamil hydrochloride 2mg/180mg m/r tablet (product) |
Product containing only trandolapril and verapamil in oral dose form (medicinal product form) |
| Trandolapril+verapamil hydrochloride 2mg/180mg prolonged-release oral tablet |
Product containing only trandolapril and verapamil in oral dose form (medicinal product form) |
| Trandolapril+verapamil hydrochloride 2mg/240mg m/r tablet (product) |
Product containing only trandolapril and verapamil in oral dose form (medicinal product form) |
| Trandolapril+verapamil hydrochloride 2mg/240mg prolonged-release oral tablet |
Product containing only trandolapril and verapamil in oral dose form (medicinal product form) |
| Trandolapril+verapamil hydrochloride 4mg/240mg m/r tablet (product) |
Product containing only trandolapril and verapamil in oral dose form (medicinal product form) |
| Trandolapril+verapamil hydrochloride 4mg/240mg prolonged-release oral tablet (product) |
Product containing only trandolapril and verapamil in oral dose form (medicinal product form) |
| Tranexamic acid 100mg/mL conventional release solution for injection 10mL vial (product) |
Tranexamic acid 100 mg/mL solution for injection |
| Tranexamic acid 100mg/mL injection (product) |
Tranexamic acid 100 mg/mL solution for injection |
| Tranexamic acid 100mg/mL intravenous solution 10mL vial (product) |
Tranexamic acid 100 mg/mL solution for injection |
| Transacylase |
Transacylase |
| Transcarbamoylase |
Transcarbamoylase |
| Transcarboxylase |
Transcarboxylase |
| Transcortin (substance) |
Corticotropin binding globulin |
| Transdermal glyceryl trinitrate allergy |
Allergy to nitroglycerin |
| Transfer of forearm tendon or muscle (procedure) |
Transposition procedure |
| Transfer of pedicle flap graft |
Reconstruction using pedicle skin flap (procedure) |
| Transformiminase |
Transformiminase |
| Transformylase |
Transhydroxymethylase |
| Transfusion reaction NOS |
Blood transfusion reaction |
| Transfusion reaction due to specific isoantibody |
Blood transfusion reaction |
| Transfusion reaction due to isoantibody |
Blood transfusion reaction |
| Transhepatic |
Transhepatic approach |
| Transhydroxymethylase |
Transhydroxymethylase |
| Transient |
Transitory |
| Transient hematological disorder, NEC (disorder) |
Transient neonatal hematological disorder |
| Transient ischemic attack clinical management plan (qualifier value) |
Transient ischemic attack clinical management plan (record artifact) |
| Transient situational disturbance |
Adjustment disorder |
| Translabial obstetric ultrasonography |
Obstetric ultrasonography with ultrasonography of genital labium |
| Transorbital |
Transorbital approach |
FHIR